ImpediMed Limited (ASX:IPD)
Australia · Delayed Price · Currency is AUD | Market Cap | 14.65M -83.6% |
| Revenue (ttm) | 14.61M +14.8% |
| Net Income | -24.91M |
| EPS | -0.01 |
| Shares Out | 3.66B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 170,318 |
| Open | 0.0040 |
| Previous Close | 0.0040 |
| Day's Range | 0.0040 - 0.0040 |
| 52-Week Range | 0.0030 - 0.0510 |
| Beta | 1.07 |
| Analysts | Buy |
| Price Target | 0.02 (+400.0%) |
| Earnings Date | Oct 30, 2026 |
About ImpediMed
ImpediMed Limited, a medical technology company, engages in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services in Australia, Europe, North America, and internationally. The company offers SOZO Digital Health Platform which transforms fluid status and tissue composition into insights with a single scan; L-Dex Analysis for Lymphedema, designed for early lymphedema detection; BodyComp Analysis; Segmental BodyComp Analysis; and HF-Dex Analysis for Heart Failure. It also provides Lymphedema Preven... [Read more]
Financial Performance
In fiscal year 2026, ImpediMed's revenue was 14.61 million, an increase of 14.85% compared to the previous year's 12.72 million. Losses were -24.91 million, 7.19% more than in 2025.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IPD stock is "Buy." The 12-month stock price target is $0.02, which is an increase of 400.00% from the latest price.
News
ImpediMed Annual report: H2 2026
ImpediMed has published its H2 2026 annual report on August 26, 2026.
ImpediMed Earnings Call Transcript: Q4 2026
Q4 saw improved cash receipts, higher unit sales, and a strengthened leadership team, with annualized cost savings of AUD 5 million set to flow through the next year. The business is focused on disciplined execution across three growing segments and aims for cash flow breakeven.
ImpediMed Slides: Q4 2026
ImpediMed has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on July 27, 2026.
ImpediMed Earnings release: Q4 2026
ImpediMed released its Q4 2026 earnings on July 27, 2026, summarizing the period's financial results.
ImpediMed Transcript: EGM 2026
Shareholders approved resolutions related to a AUD 15.2 million capital raise, including placements, options, and director securities. Funds will reduce debt and support growth in key health markets, with a path to cash flow breakeven by FY2028. Voting was conducted by poll, with results to be announced.
ImpediMed Earnings release: Trading update
ImpediMed released its earnings on May 3, 2026, summarizing the period's financial results.
ImpediMed Slides: Investor presentation
ImpediMed has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.
ImpediMed Earnings release: Q3 2026
ImpediMed released its Q3 2026 earnings on April 29, 2026, summarizing the period's financial results.
ImpediMed Transcript: Investor update
A new CEO with strong U.S. medtech experience has been appointed to accelerate commercial execution, building on robust operational foundations and expanded reimbursement coverage. The company achieved solid U.S. sales growth in Q3 and continues to focus on cost discipline.
ImpediMed Quarterly report: H1 2026
ImpediMed has published its H1 2026 quarterly earnings report on February 25, 2026.
ImpediMed Slides: H1 2026
ImpediMed has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 25, 2026.
ImpediMed Earnings release: H1 2026
ImpediMed released its H1 2026 earnings on February 25, 2026, summarizing the period's financial results.
ImpediMed Earnings Call Transcript: Q2 2026
Quarterly revenue hit a record AUD 3.9M, up 18% year-on-year, with strong rest of world sales and improved cash flow. Over 700 sales opportunities are in the pipeline, and new FDA clearances and product launches support growth in heart health and wellness segments.
ImpediMed Earnings release: Q2 2026
ImpediMed released its Q2 2026 earnings on January 28, 2026, summarizing the period's financial results.
ImpediMed Slides: Q2 2026
ImpediMed has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on January 28, 2026.
ImpediMed Transcript: AGM 2025
The meeting reviewed strong revenue and ARR growth, highlighted expansion into new U.S. health markets, and discussed board expertise and governance. Shareholders engaged on sales metrics, staffing, and global strategy, with management outlining plans for further growth and operational efficiency.
ImpediMed Slides: FY 2025
ImpediMed has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 17, 2025.
ImpediMed Earnings Call Transcript: Q1 2026
SOZO platform adoption is expanding across lymphedema, heart failure, and body composition, with record revenue and ARR growth. Reimbursement coverage has surged, and a revamped sales team is expected to drive a rebound in U.S. sales next quarter.
ImpediMed Earnings release: Q1 2026
ImpediMed released its Q1 2026 earnings on October 29, 2025, summarizing the period's financial results.
ImpediMed Slides: Q1 2026
ImpediMed has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on October 29, 2025.